Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene - PubMed (original) (raw)
Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene
C Maier et al. Br J Cancer. 2005.
Abstract
To date, germline mutations have been found in three candidate genes for hereditary prostate cancer: ELAC2 at 17p11, RNASEL at 1q25 and MSR1 at 8p22. RNASEL, encoding the 2',5'-oligoadenylate-dependant RNase L, seems to have rare mutations in different ethnicities, such as M1I in Afro-Americans, E265X in men of European descent and 471delAAAG in Ashkenazi Jews. In order to evaluate the relevance of RNASEL in the German population, we sequenced its open reading frame to determine the spectrum and frequency of germline mutations. The screen included 303 affected men from 136 Caucasian families, of which 45 met the criteria for hereditary prostate cancer. Variants were analysed using a family-based association test, and genotyped in an additional 227 sporadic prostate cancer patients and 207 controls. We identified only two sib pairs (1.4% of our families) cosegregating conspicuous RNASEL variants with prostate cancer: the nonsense mutation E265X, and a new amino-acid substitution (R400P) of unknown functional relevance. Both alleles were also found at low frequencies (1.4 and 0.5%, respectively) in controls. No significant association of polymorphisms (I97L, R462Q and D541E) was observed, neither in case-control analyses nor by family-based association tests. In contrast to previous reports, our study does not suggest that common variants (i.e. R462Q) modify disease risk. Our results are not consistent with a high penetrance of deleterious RNASEL mutations. Due to the low frequency of germline mutations present in our sample, RNASEL does not have a significant impact on prostate cancer susceptibility in the German population.
Figures
Figure 1
Pedigrees with conspicuous RNASEL alleles. Carriers of variants are indicated by one filled circle. Two open circles represent wild-type genotypes.
Similar articles
- Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.
Rökman A, Ikonen T, Seppälä EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. Rökman A, et al. Am J Hum Genet. 2002 May;70(5):1299-304. doi: 10.1086/340450. Epub 2002 Apr 8. Am J Hum Genet. 2002. PMID: 11941539 Free PMC article. - Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
Nupponen NN, Wallén MJ, Ponciano D, Robbins CM, Tammela TL, Vessella RL, Carpten JD, Visakorpi T. Nupponen NN, et al. Genes Chromosomes Cancer. 2004 Feb;39(2):119-25. doi: 10.1002/gcc.10308. Genes Chromosomes Cancer. 2004. PMID: 14695991 - Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
Beuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, Leach RJ. Beuten J, et al. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):588-99. doi: 10.1158/1055-9965.EPI-09-0864. Epub 2010 Jan 19. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20086112 Free PMC article. - Perspective: prostate cancer susceptibility genes.
Simard J, Dumont M, Soucy P, Labrie F. Simard J, et al. Endocrinology. 2002 Jun;143(6):2029-40. doi: 10.1210/endo.143.6.8890. Endocrinology. 2002. PMID: 12021166 Review. - Implications for RNase L in prostate cancer biology.
Silverman RH. Silverman RH. Biochemistry. 2003 Feb 25;42(7):1805-12. doi: 10.1021/bi027147i. Biochemistry. 2003. PMID: 12590567 Review.
Cited by
- Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease.
Rusmevichientong A, Chow SA. Rusmevichientong A, et al. Immunol Res. 2010 Dec;48(1-3):27-39. doi: 10.1007/s12026-010-8165-y. Immunol Res. 2010. PMID: 20717743 - Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.
Ahmed M, Eeles R. Ahmed M, et al. Future Sci OA. 2015 Dec 18;2(1):FSO87. doi: 10.4155/fso.15.87. eCollection 2016 Mar. Future Sci OA. 2015. PMID: 28031937 Free PMC article. Review. - XMRV Discovery and Prostate Cancer-Related Research.
Kang DE, Lee MC, Das Gupta J, Klein EA, Silverman RH. Kang DE, et al. Adv Virol. 2011;2011:432837. doi: 10.1155/2011/432837. Epub 2011 Jun 21. Adv Virol. 2011. PMID: 22312343 Free PMC article. - Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.
Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA. Robbins CM, et al. Prostate. 2008 Dec 1;68(16):1790-7. doi: 10.1002/pros.20841. Prostate. 2008. PMID: 18767027 Free PMC article. - Inflammation in prostate carcinogenesis.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. De Marzo AM, et al. Nat Rev Cancer. 2007 Apr;7(4):256-69. doi: 10.1038/nrc2090. Nat Rev Cancer. 2007. PMID: 17384581 Free PMC article. Review.
References
- Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30: 181–184 - PubMed
- Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150: 797–802 - PubMed
- Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32: 581–583 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous